Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immutep Ltd ( (AU:IMM) ) has shared an update.
JPMorgan Chase & Co. and its affiliates have notified Immutep Ltd that they have ceased to be a substantial shareholder in the company as of 6 May 2026. The change follows a series of securities lending, rehypothecation, and proprietary trading transactions across several JPMorgan entities, resulting in their aggregate holding falling below the substantial holder threshold.
The move alters Immutep’s institutional shareholder base and may slightly reduce the influence of JPMorgan-linked entities on voting outcomes at shareholder meetings. While the filing is largely technical and reflects shifts in JPMorgan’s trading and lending positions, it signals a rebalancing of exposure by a major global financial institution and may prompt investors to review recent trading dynamics in Immutep’s stock.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments, particularly in the area of cancer and autoimmune diseases. The company leverages its expertise in LAG-3 immune control mechanisms to advance a pipeline of clinical and preclinical programs aimed at enhancing patient responses to existing therapies and addressing unmet medical needs in global healthcare markets.
YTD Price Performance: -85.54%
Average Trading Volume: 43,564,953
Technical Sentiment Signal: Sell
Current Market Cap: A$88.42M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.